研究单位：[1]Capital Medical University Xuanwu Hospital,Beijing,Beijing,China,100053[2]West China Hospital[3]The First Affiliated Hospital of Zhengzhou University[4]Tianjin Huanhu Hospital[5]Shandong Provincial Hospital[6]Peking University Third Hospital[7]Shanghai Mental Health Center[8]Beijing Tiantan Hospital[9]Xiangya Hospital of Central South University[10]First Affiliated Hospital of Chongqing Medical University[11]Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University[12]The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School[13]Sichuan Provincial People's Hospital[14]Brain Hospital Affiliated to Guangzhou Medical University[15]Sir Run Run Shaw Hospital
This research is a randomized, double-blind, placebo-parallel controlled, and multi-center clinical study in China, aiming to evaluate the tolerability, efficacy, and safety of JT821 (Ketogenic Diet) in the treatment of mild to moderate Alzheimer's disease. The ketogenic diet (KD) is a low-carbohydrate, adequate protein and high-fat diet. KD was shown to be effective in treating different neurodegenerative diseases.
